

# Vonjo (pacritinib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Vonjo (pacritinib)	May be subject to quantity limit

## **APPROVAL CRITERIA**

Requests for Vonjo (pacritinib) may be approved if the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has a diagnosis of intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; **AND**
- III. Individual has a platelet count below 50 X 10<sup>9</sup>/L.

Requests for Vonjo may not be approved for the following:

- I. Individual is using in combination with moderate or strong CYP3A4 inhibitors or inducers (e.g. clarithromycin, rifampin); **OR**
- II. Individual is using in combination with CYP1A2, CYP3A4, P-gp, BCRP, or OCT-1 substrates (e.g. digoxin, erythromycin, cyclosporin); **OR**
- III. Individuals with moderate (Child-Pugh B) or severe hepatic (Child-Pugh C) impairment; **OR**
- IV. Individuals with an eGFR <30 mL/min.

## **Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2022. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed on March 3, 2022.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2022 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on March 3, 2022
6. Vonjo (pacritinib) capsule [package insert]. Seattle, WA: CTI BioPharma. March 2022. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/208712s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf) Accessed March 3, 2022.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.